Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

导出 OA

翻译打印收藏纠错

作者： Juanjuan,Zhao ^[1] ; Quan,Yuan ^[2] ; Haiyan,Wang ^[3] ; Wei,Liu ^[1] ; Xuejiao,Liao ^[2] ; Yingying,Su ^[3] ; Xin,Wang ^[1] ; Jing,Yuan ^[2] ; Tingdong,Li ^[3] ; Jinxiu,Li ^[1] ; Shen,Qian ^[4] ; Congming,Hong ^[2] ; Fuxiang,Wang ^[3] ; Yingxia,Liu ^[5] ; Zhaoqin,Wang ^[1] ; Qing,He ^[2] ; Zhiyong,Li ^[3] ; Bin,He ^[4] ; Tianying,Zhang ^[4] ; Yang,Fu ^[6] ; Shengxiang,Ge ^[6] ; Lei,Liu ^[6] ; Jun,Zhang ^[3] ; Ningshao,Xia ^[2] ; Zheng,Zhang ^[3]

作者单位： Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, China. ^[1] The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health and School of Life Science, Xiamen University, Xiamen, China. ^[2] School of Public Health, Xiamen University, Xiamen, China. ^[3] Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China. ^[4] Department of Critical Care Medicine, Shenzhen Third People's Hospital, Shenzhen, China. ^[5] The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China. ^[6] School of Medicine, Southern University of Science and Technology, Shenzhen, China. ^[7]

关键词 COVID-19 SARS-CoV-2 antibody